Screening of siRNA Nanoparticles for Delivery to Airway Epithelial Cells Using High Content Analysis
Delivery of siRNA to the lungs via inhalation offers a unique opportunity to develop novel methods of treating a range of poorly treated respiratory conditions. However progress has been greatly hindered by safety and delivery issues. This study developed a high-throughput method for screening novel nanotechnologies for pulmonary siRNA delivery
Following physico-chemical analysis, the ability of PEI-PEG/siRNA nanoparticles to facilitate siRNA delivery was determined using high content analysis (HCA) in Calu-3 cells. Results obtained from HCA were validated using confocal microscopy. Finally, cytotoxicity of the PEI-PEG/siRNA particles was analysed by HCA using the Cellomics® multiparamter cytotoxicity assay.
PEI-PEG/siRNA nanoparticles facilitated increased siRNA uptake and luciferase knockdown in Calu-3 cells compared to PEI/siRNA.
CommentsThis article is also availble at http://www.future-science.com/doi/abs/10.4155/tde.11.73
Published CitationHibbitts A, Lieggi N, McCabe O, Thomas W, Barlow J, O’Brien F, Cryan SA. Screening of siRNA Nanoparticles for Delivery to Airway Epithelial Cells Using High Content Analysis. Therapeutic Delivery. 2011;2(8):987-999.
- Molecular Medicine
- School of Pharmacy and Biomolecular Sciences
- Beaumont Hospital